Advertising

Five things for pharma marketers to know: Friday, May 22

Five things for pharma marketers to know: Friday, May 22

By

Amgen's PSCK9 inhibitor gets a position opinion in the EU; the FDA plans to study how spouses influence perception of DTC ads; Botox may relieve depression

Centron scuttles HealthStar name, sells LehmanMillet

Centron scuttles HealthStar name, sells LehmanMillet

By

The new Centron includes renamed medical education, public relations and market access divisions.

Everyday Health looks to compete for pharma TV budgets

Everyday Health looks to compete for pharma TV budgets

By

The digital health firm is expanding services to pharma customers, offering to help drugmakers maximize spending on TV and video.

WebMD profit jumps 60% in the first quarter

WebMD profit jumps 60% in the first quarter

By

The company said revenue from pharmaceutical and medical device sponsorships and advertisements rose 10.7% but the company put some initiatives on hold.

Study shows women view health differently than industry thinks they do

Study shows women view health differently than industry thinks they do

By

A deep dive by the think tank Center for Talent Innovation indicates pharma and payers need to widen their definition of health when communicating with women.

Omnicom reports boost in Q1 net income

The holding company said pharma and health made up 11% of revenues during the first three months of the year.

Patients do not feel connected to pharma

Patients do not feel connected to pharma

By

Wego Health says fixing this problem requires incorporating patient perspectives before and after a product launch.

How to Make DTC Ad 'Warnings' More Effective

How to Make DTC Ad 'Warnings' More Effective

A more general warning encourages consumers to engage in a personal discussion with their doctor about a drug, and it promotes engagement with longer-format printed or digitally-delivered information.

Five things for pharma marketers to know: Friday, March 13

Five things for pharma marketers to know: Friday, March 13

By

J&J sues GlaxoSmithKline over Flonase ads, CDC report finds patients with invasive cancer are living for five years or longer have diagnosis, and Bristol-Myers Squibb resubmits its HCV treatment.

Mobile carries WebMD forward

Mobile carries WebMD forward

By

Smartphones drove network traffic.

AdAge: advertising's penalty box is empty

The Trustworthy Accountability of National Advertisers launched its naming-names initiative in November, but the list is empty.

Five things for pharma marketers to know: Friday, February 20

Five things for pharma marketers to know: Friday, February 20

By

23andMe is back in the DTC game; Sanofi has named its new CEO; drug companies are contemplating a pay-for-performance sales model.

FDA updates DTC ad policy on risk information

FDA updates DTC ad policy on risk information

By

FDA posted a revised draft guidance document on its brief summary and adequate directions for use concerning risk information in DTC print ads to reflect "recent social science research."

OPDP finds many flaws with Luitpold video

OPDP finds many flaws with Luitpold video

By

The list of objections by the Office of Prescription Drug Promotion, which oversees medical advertising, is a familiar one, and includes concerns such as claims that go beyond the approved indication.

Five things for pharma marketers to know: Tuesday, February 10

Five things for pharma marketers to know: Tuesday, February 10

By

FDA's latest guidance says it is ok to reduce the amount of risk information in print ads, Google amplifies the health information it will serve up with searches and HBO's John Oliver takes on pharmaceutical marketing.

Guidemark Health jumpstarts rebrand, brings on big-agency grad

Guidemark Health jumpstarts rebrand, brings on big-agency grad

By

Tina Fascetti is the mid-sized agency's new Chief Creative Officer. CEO Matt Brown (and ICC Lowe alum) tells MM&M the new Guidemark is just getting started.

FDA to study impact of shorter DTC risk list

FDA to study impact of shorter DTC risk list

By

The FDA is looking into whether abbreviated risk information is a good idea for DTC.

Medical Advertising Hall of Fame taps new members

MAHF 2015 Heritage Ad Awards will be given to campaigns for Bentyl, Hytrin and Navane

Ariz. film, entertainment agency adds depth to Fingerpaint

Ariz. film, entertainment agency adds depth to Fingerpaint

By

With the purchase of Olson Communications, the agency aims to serve clients eager for expertise from outside the healthcare industry.

HCB Health lands Alcon AOR

The Austin agency says it beat out FCB, Ogilvy CommonHealth, GSW Worldwide and H4B Chelsea for the work.

The Planning Shop joins Omnicom

The London healthcare brand and research agency will be part of Omnicom's DAS Group.

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

OPDP says phentermine site thin on details

OPDP says phentermine site thin on details

By

The bad-ad watchdog says the promotional website for the weight-loss medication Suprenza leaves out too much information.

FDA examines DTC close up

FDA examines DTC close up

By

The regulator's latest study will use eye-tracking tools.

OPDP takes on sales aid for alcohol drug

OPDP takes on sales aid for alcohol drug

By

The advertising watchdog gave drugmaker Alvogen 15 days to make amends.

Publicis, Facebook ink deal

The Omnicom-Publicis deal may have been scuttled, but the hunger for deals remains.

Takeda admits running bad ads

The company said it used "inappropriate expressions" in promotions of a blood pressure medication.

NABP seeks pharmacy oversight

The National Association of Boards of Pharmacy says about 97% of surveyed pharmacy sites fail to comply with laws.

Raid at Novartis Tokyo

The reason: Diovan.

FDA may ditch some TV ad requirements

A consumer survey will shape the regulator's position.


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.

Email Newsletters